MYD88 and diffuse large B-cell lymphoma: In addition to CD79A/CD79B and CARD11 mutations, ~40% of ABC DLBCL cases harbor a gain-of-function mutations (L265P, V217F, S219C, M232T, S243N, T294P amino acid substitution) in Myeloid differentiation primary response 88 (MYD88) (21).